Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefadroxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | HPGD | P15428 | 3/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefadroxil SCHEMBL16072813 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL3984782 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL524155 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL3984780 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL19123520 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL151320 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9650920 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL13698957 | 1.00 | MAPT (1.00) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL9807365 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 | |
| Cefadroxil SCHEMBL1821440 | 0.99 | MAPT (0.98) | MAPTHSD17B10KMT2AMEN1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109971743-B | Penicillin G acylase mutant derived from achromobacter CCM4824 and application thereof | 艾美科健株式会社 | 2022-09-06 | — | — | CN | disclosed |
| CN-105534937-B | A kind of cefadroxil tablet and preparation method thereof | 石药集团欧意药业有限公司 | 2019-12-03 | — | — | CN | disclosed |
| CN-109971743-A | From the penicillin G acylase mutant of achromobacter CCM4824 and its application | 艾美科健株式会社 | 2019-07-05 | — | — | CN | disclosed |
| CN-109971742-A | From the penicillin G acylase mutant of achromobacter CCM 4824 and its application | 艾美科健株式会社 | 2019-07-05 | — | — | CN | disclosed |
| CN-109776573-A | Cefadroxil preparation treats the new indication of female reproductive system infection | 上海金城药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| EP-3094492-B1 | LAMINATED BAG FOR PHARMACEUTICALS | CENTRIENT PHARMACEUTICALS NETHERLANDS B V (NL) | 2019-05-15 | — | — | EP | disclosed |
| CN-105640895-B | A kind of cefadroxil granular preparation and preparation method thereof | 石药集团欧意药业有限公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3094492-A1 | LAMINATED BAG FOR PHARMACEUTICALS | DSM Sinochem Pharmaceuticals Netherlands B.V. (NL) | 2016-11-23 | — | — | EP | disclosed |
| US-20160331638-A1 | LAMINATED BAG FOR PHARMACEUTICALS | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2016-11-17 | — | — | US | disclosed |
| CN-105640895-A | Cefadroxil granular preparation and preparation method thereof | 石药集团欧意药业有限公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-105534937-A | Cefadroxil tablet and preparation method thereof | CSPC PHARMACEUTICAL GROUP OUYI PHARMA CO LTD | 2016-05-04 | — | — | CN | disclosed |
| WO-2015107016-A1 | LAMINATED BAG FOR PHARMACEUTICALS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2015-07-23 | — | — | WO | disclosed |
| CN-104546755-A | Cefadroxil composition freeze-drying tablet and preparation method thereof | HAINAN WEKON PHARMACEUTICAL QIANSHAN CO LTD | 2015-04-29 | — | — | CN | disclosed |
| CN-102247331-B | Cefadroxil chewable tablets and preparation method thereof | ZHUHAI KINHOO PHARMACEUTICAL CO LTD | 2012-09-26 | — | — | CN | disclosed |
| CN-102247331-A | Cefadroxil chewable tablets and preparation method thereof | ZHUHAI KINHOO PHARMACEUTICAL CO LTD | 2011-11-23 | — | — | CN | disclosed |
| CN-1857230-A | Cefadroxil preparation and its preparing process | XINYI BAILUDA PHARMACEUTICAL I (CN) | 2006-11-08 | — | — | CN | disclosed |
| CN-1682739-A | Cefadroxil dry suspension and preparing method | OUYI PHARMACEUTICAL CO LTD SHI (CN) | 2005-10-19 | — | — | CN | disclosed |
| CN-1663614-A | Compound ambroxol and cephalosporins preparation and application thereof | BEIJING FU KANG REN BIO PHARM (CN) | 2005-09-07 | — | — | CN | disclosed |
| CN-1618428-A | Cefadroxil oral disintegrant tablet, and its prepn. method | ZHONGQI PHARMACEUTICAL TECH SH (CN) | 2005-05-25 | — | — | CN | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | MAPT 767/4885HSD17B10 3594/4885KMT2A 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.